Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation
Inclusion Criteria:
- group A: first diagnosis of PCNSL, histologically confirmed
- group B: relapse or progression of PCNSL after MTX containing chemotherapy
- age 18 - 65 years
- not legally incompetent, physically or mentally incapable of giving consent
- written signed and dated informed consent of the legal representative and - if
possible - of the patient
Exclusion Criteria:
- manifestations of further lymphoma outside the CNS
- sero-positive for HIV
- severe pulmonary, cardiac, hepatic, renal impairment
- neutrophil count < 2.000/µl, platelet count < 100.000/µl
- pulmonary disease with IVC < 55%, DLCO < 40%
- cardiac ejection fraction < 50%, uncontrolled malign arrhythmia
- creatinine > 1,5 mg% or creatinine-clearance < 50ml/min
- bilirubin > 2mg/dl
- ascites or pleural effusion (> 500ml)
- pregnancy o r lactation
- women with childbearing potential without sufficient contraception
- participation in another clinical trial within the last 30 days prior to the begin or
parallel to this study
- known or current drug or alcohol abuse
- known hypersensitivity against methotrexate, cytarabine, thiotepa, BCNU rituximab,
leukovorin, dexamethasone, neupogen and neulasta.